Fda denies citizen petitions filed on behalf of short selling clients

Austin, texas, feb. 10, 2022 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company focused on alzheimer's disease, announced today that the u.s. food and drug administration ("fda") denied a citizen petition that was filed in august 2021 by an attorney on behalf of short-selling clients. fda also denied four supplements to the august 2021 citizen petition. fda also denied a september 2021 citizen petition, and a supplement, that were also filed by the same attorney on behalf of short-selling clients.
SAVA Ratings Summary
SAVA Quant Ranking